Skip to main content
Premium Trial:

Request an Annual Quote

ExonHit Licenses Merck Rights to RNA Splicing Microarray Patent

NEW YORK (GenomeWeb News) - ExonHit Therapeutics has granted Merck a license to its RNA splicing microarray patent, ExonHit said yesterday.
 
The non-exclusive license gives rights to the patent -- US No. 6,881,571, titled “Qualitative Differential Screening” -- for research use only. The patent has claims directed to microarrays optimized to monitor RNA splicing events, the company said.
 
ExonHit does not expect to receive more than $150,000 in revenues per year under this agreement.
 
Additional details were not disclosed.

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.